drugset / Trial / NCT04822337
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Phase 1/2
Active not recruiting
70 enrolled
Wake Forest University Health Sciences
Amgen · collabGlaxoSmithKline · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
Timeline
- Start
- 2021-05-19
- Primary completion
- 2029-04
- Completion
- 2032-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | 1.4 mg/kg | — |
| Subject | Belantamab mafodotin | Monoclonal antibody | 1.9 mg/kg | — |
| Background | Carfilzomib | Other / unclassified | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Lenalidomide | Other / unclassified | — | — |